^
Association details:
| Biomarker: | EGFR exon 20 insertion + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
991P - EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
Published date:
09/05/2022
Excerpt:
Real-world-data (RWD) of 159 advanced NSCLC patients with EGFR exon 20 insertion in the timeframe of 2014-2020 were analyzed. TP53 mutation was the most common co-occurring mutation in 69 (43.6%) patients….In patients with co-occurring TP53, patients who received ICB (n=33) had longer OS than those without ICB exposure...these patients seem to benefit from the ICB, especially at the beginning of their treatment pathway.
